DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cbdpzz/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry t
| < Prev | Next > |
|---|
